Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date,Drug Design, Development and Therapy

当前位置： X-MOL 学术 › Drug Des. Dev. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
Drug Design, Development and Therapy ( IF 4.7 ) Pub Date : 2021-02-11 , DOI: 10.2147/dddt.s240854
Mohamad Moussa ₁ , Athanasios Papatsoris ₂ , Mohamed Abou Chakra ₁ , Athanasios Dellis _{2,

3}

Affiliation

Abstract: Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.

Keywords: enfortumab vedotin, bladder cancer, metastasis, urothelial cancer

中文翻译：

Enfortumab Vedotin 治疗尿路上皮癌的概况：迄今为止的证据

摘要：当今晚期和转移性尿路上皮癌的治疗前景不断发展。最近监管机构批准 enfortumab vedotin (EV) 用于治疗晚期尿路上皮癌，证实了抗体药物偶联物不断发展的作用。 EV 在经过大量治疗的局部晚期或转移性尿路上皮癌患者中表现出良好的特征。早期生存报告表明，在难治人群中具有显着的抗肿瘤功效以及相当可接受的安全性。

关键词: enfortumab vedotin, 膀胱癌, 转移, 尿路上皮癌

更新日期：2021-04-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文